Merck Sharp + Dohme Corp.

Sanofi

Ra Pharmaceuticals, Inc.

Indiana University

Msd Italia S.r.l.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

Corteria Pharmaceuticals

Alessia Santoprete

Elisabetta Bianchi

Raffaele Ingenito

Olivier Duclos

Sergio Mallart

Stéphane Illiano

Paola Magotti

Claire Minoletti-Hochepied

Thomas Joseph Tucker

Yusheng Xiong

Angela Dawn Kerekes

Hyewon Youm

Danila Branca

Chengwei Wu

Alonso Ricardo

Mark W Embrey

Nicolas Cedric Boyer

Immacolata Conte

Stefania Colarusso

Joseph R Stringer

Derek M LaPlaca

Roberto Costante

Richard Dennis DiMarchi

Hubert B Josien

Andreas Evers

Eric J Gilbert

Frank Marguet

Sookhee Nicole Ha

Fa-Xiang Ding

Antonello Pessi

Nis Halland

Aurash Shahripour

Willy Costantini

Abbas M Walji

Joseph M Metzger

Paul E Carrington

Brian P Ward

Philip Janiak

Paolo Ingallinella

Donald J Marsh

Ralf Elvert

Ranabir Sinha Roy

George J Eiermann

Denis Brasseur

Philippe Beauverger

Elena Capito

Alessandro Pocai

Ziyu Li

Richard Dimarchi

Martina Tripepi

Laurence Lucats

Laetitia Ledein

Daniela Roversi

Marie-Laure Ozoux

Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.

Cyclic polypeptides for PCSK9 inhibition

A biologically active single chain Relaxin peptide having the formula N-Ac-L-E-G-R-E-K-V-R-A-X-I-X-X-E-G-X-S-T-F-S-X-R-A-X-NH-C, or a salt of solvate thereof, is described.

Modified lipidated relaxin B chain peptides and their therapeutic use

Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R, and Rare as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions 

PCSK9 antagonists bicyclo-compounds

Provided is a biologically active single chain Relaxin peptide having the following formula (I):N-Ac-(E)-X-E-G-R-E-X-V-R-X-X-I-X-X-E-G-X-S-X-X-X-X-R-(X)-(X)-(K)-(X)-(gE)-X-C; or a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.

Modified lipidated Relaxin B chain peptides and their therapeutic use

Provided is a biologically active single chain Relaxin peptide having the following formula (I): N-X-(E)-X-E-G-R-E-X-V-R-X-X-I-X-X-E-G-X-S-X-X-X-X-R-(X)-(X)-(X)-NH-C. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, or a pharmaceutically acceptable salt or a solvate thereof. Further provided is the peptide, a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition for use as a medicament.

Modified relaxin B chain peptides and their therapeutic use

Provided is a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO 105): N-Ac-X-E-G-R-E-X-V-R-X-X-I-X-X-E-G-X-S-X-X-X-X-X-X-X-NH-Cor a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one biologically active single chain Relaxin peptide. Uses of the peptide or the pharmaceutical composition as a medicament are also provided.

Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.

Oxyntomodulin analogs

Growing community of inventors

Pomezia, Italy

Alessia Santoprete